Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
IEXLiveblog: Sell-off
Categorie: Beurs vandaag
Door
op donderdag 29 juni 2017
Views: 9.892
Meld u aan voor de dagelijkse Beursupdate
Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!
Van je hobby je werk maken, is dat slim? Nick Bakker doet dat als Market Watcher bij IEX. Hij verzorgt dagelijks het Fondsenrondje, de Slotcall en het IEXNieuws. Daarin houdt Nick u op de hoogte van al het beursnieuws, de AEX en alles wat er maar speelt bij Nederlandse aandelen.
Beleggen, stockpicken, maar ook speculeren. ...
Meer over Nick Bakker
Recente artikelen van Nick Bakker
jul '18
Liveblog: Trump en BAM
3
jul '18
Liveblog: Microsoft
7
jul '18
Slotcall: Shell en Unies
3
in de cache van google is het volgende te vinden over cardioprolific: THE GENESIS™ SYSTEM HARDWARE: Fully integrated system includes Generator, Transducer, Irrigation Pump and Footswitch Generator - Converts AC line power into high frequency current Transducer - Piezoelectric crystals assembly converts high frequency current into ultrasound energy using a proprietary mode of operation at approximately 20kHz frequency Irrigation Pump - Delivers saline during ultrasound energy application Footswitch - Activates System ON/OFF The Genesis System also includes a state of art aspiration feature and is suitable for endovascular thrombectomy, as well as, for crossing Chronic Total Occlusions. CATHETER: The Genesis catheter with a rapid connection and disconnection feature propagates ultrasound surface waves to the treatment area. After ultrasound exposure, Paclitaxel in mixture with contrast is delivered to the vessel wall, and aspirated after the procedure. No need for a sterile sleeve. en: CardioProlific’s Genesis™ System applies ultrasound energy at 20kHz frequency to change lesion compliance by creating micro-channels and micro-cracks within the media/intima calcium to facilitates therapeutic drug delivery to the vessel wall. Our unique methods ensure drug delivery through calcific plaque and even distribution of the therapeutic drug within the vessel wall, regardless of lesion location, lesion length and vessel diameter. The basic science and feasibility testing to support our unique approach has been successfully demonstrated in-vitro, in-vivo and in OUS Clinical Trial. Resulting data suggests superiority of our technology in patient with severe calcifications where there are limited treatment options available today.
Aantal posts per pagina:
20
50
100